We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
News & insights
News: 18 SEPTEMBER 2020
We have advised Apax Partners and its portfolio company Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), on the acquisition of the…Read more
Publications: 29 JULY 2020
Setting the stage Since long, discussions in Belgium have been ongoing as to who needs to prove that a patient was sufficiently informed about his/her treatment and its potential complications. With…Read more
News: 20 JULY 2020
An A&O team comprising UK, German, U.S. and Dutch lawyers is advising GlaxoSmithKline (GSK) on its strategic collaboration with German biotech company CureVac for the research, development and…Read more
News: 10 JULY 2020
Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…Read more